PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)

NCT03658447 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: Pembrolizumab
DRUG: 177Lu-PSMA

Sponsor

Peter MacCallum Cancer Centre, Australia